Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Longeveron Inc. LGVN

MissionIRNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial

Posted on October 5, 2023 by MissionIR

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Posted on September 27, 2023 by MissionIR

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who participated in … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

MissionIRNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Posted on September 22, 2023 by MissionIR

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

Posted on September 14, 2023 by MissionIR

Longeveron (NASDAQ: LGVN), a clinical-stage company, is focused on developing cellular therapy primarily for conditions with a clear unmet medical need. The company is guided by the mission to advance cell-based product candidates into pivotal Phase 3 trials, with the … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

MissionIRNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter

Posted on September 11, 2023 by MissionIR

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has issued a letter to its stockholders. The letter, from CEO … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’

Posted on September 8, 2023 by MissionIR

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

MissionIRNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Posted on September 5, 2023 by MissionIR

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment